The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients

Hengrui Medicine

Status and phase: Unknown; Phase 1

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Placebo; Drug: SHR3824

Study type: Interventional

Funder types: Industry

Identifiers

NCT02366351

SHR3824-107

Details and patient eligibility

About

The purpose of this study is to obtain information on PK/PD, efficacy and safety of SHR3824 over 12 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing the effect of SHR3824 to placebo when given in oral doses.

Enrollment: 168 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have a diagnosis of type 2 diabetes mellitus;
• Hemoglobin A1c levels >=7.5% and <=10.5%;
• Body mass index (BMI) 25 to 45 kg/m2;
• Patient either has not been previously treated with antihyperglycemic medication or has not been treated with antihyperglycemic in the last 10 weeks.

Exclusion criteria

• Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);
• Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy);
• Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period;
• History of myocardial infarction, unstable angina, or cerebrovascular disorder within 6 months before the start of the run-in period;
• Past or current history of malignant tumor;
• Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms;
• Pregnant women, lactating mothers, or women of childbearing potential;
• Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

168 participants in 4 patient groups

SHR3824 Placebo

Experimental group

Description:

once daily, 12 weeks

Treatment:

Drug: Placebo

SHR3824 5 mg

Experimental group

Description:

once daily, 12 weeks

Treatment:

Drug: SHR3824

SHR3824 10 mg

Experimental group

Description:

once daily, 12 weeks

Treatment:

Drug: SHR3824

SHR3824 20 mg

Experimental group

Description:

once daily, 12 weeks

Treatment:

Drug: SHR3824